Literature DB >> 19733654

Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion.

Paulina Pettinelli1, Talía Del Pozo, Julia Araya, Ramón Rodrigo, A Verónica Araya, Gladys Smok, Attila Csendes, Luis Gutierrez, Jorge Rojas, Owen Korn, Fernando Maluenda, Juan C Diaz, Guillermo Rencoret, Italo Braghetto, Jaime Castillo, Jaime Poniachik, Luis A Videla.   

Abstract

Sterol receptor element-binding protein-1c (SREBP-1c) and peroxisome proliferator-activated receptor-alpha (PPAR-alpha) mRNA expression was assessed in liver as signaling mechanisms associated with steatosis in obese patients. Liver SREBP-1c and PPAR-alpha mRNA (RT-PCR), fatty acid synthase (FAS) and carnitine palmitoyltransferase-1a (CPT-1a) mRNA (real-time RT-PCR), and n-3 long-chain polyunsaturated fatty acid (LCPUFA)(GLC) contents, plasma adiponectin levels (RIA), and insulin resistance (IR) evolution (HOMA) were evaluated in 11 obese patients who underwent subtotal gastrectomy with gastro-jejunal anastomosis in Roux-en-Y and 8 non-obese subjects who underwent laparoscopic cholecystectomy (controls). Liver SREBP-1c and FAS mRNA levels were 33% and 70% higher than control values (P<0.05), respectively, whereas those of PPAR-alpha and CPT-1a were 16% and 65% lower (P<0.05), respectively, with a significant 62% enhancement in the SREBP-1c/PPAR-alpha ratio. Liver n-3 LCPUFA levels were 53% lower in obese patients who also showed IR and hipoadiponectinemia over controls (P<0.05). IR negatively correlated with both the hepatic content of n-3 LCPUFA (r=-0.55; P<0.01) and the plasma levels of adiponectin (r=-0.62; P<0.005). Liver SREBP-1c/PPAR-alpha ratio and n-3 LCPUFA showed a negative correlation (r=-0.48; P<0.02) and positive associations with either HOMA (r=0.75; P<0.0001) or serum insulin levels (r=0.69; P<0.001). In conclusion, liver up-regulation of SREBP-1c and down-regulation of PPAR-alpha occur in obese patients, with enhancement in the SREBP-1c/PPAR-alpha ratio associated with n-3 LCPUFA depletion and IR, a condition that may favor lipogenesis over FA oxidation thereby leading to steatosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733654     DOI: 10.1016/j.bbadis.2009.08.015

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  73 in total

Review 1.  Management of NAFLD: a stage-based approach.

Authors:  Mary E Rinella; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

2.  Moro orange juice prevents fatty liver in mice.

Authors:  Federico Salamone; Giovanni Li Volti; Lucilla Titta; Lidia Puzzo; Ignazio Barbagallo; Francesco La Delia; Shira Zelber-Sagi; Michele Malaguarnera; Pier Giuseppe Pelicci; Marco Giorgio; Fabio Galvano
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

3.  Resistance training restores the gene expression of molecules related to fat oxidation and lipogenesis in the liver of ovariectomized rats.

Authors:  Mateus Moraes Domingos; Maria Fernanda Cury Rodrigues; Uliana Sbeguen Stotzer; Danilo Rodrigues Bertucci; Markus Vinicius Campos Souza; Diego Adorna Marine; Camila do Valle Gomes Gatto; Heloisa Sobreiro Selistre de Araújo; Sérgio Eduardo de Andrade Perez
Journal:  Eur J Appl Physiol       Date:  2011-08-10       Impact factor: 3.078

4.  Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation.

Authors:  Bing Zhou; Dan-Li Zhou; Xiao-Hong Wei; Rong-Yu Zhong; Jie Xu; Liao Sun
Journal:  Acta Pharmacol Sin       Date:  2017-03-27       Impact factor: 6.150

Review 5.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

6.  Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.

Authors:  Vanessa Souza-Mello
Journal:  World J Hepatol       Date:  2015-05-18

7.  Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity.

Authors:  Nazarii Kobyliak; Tetyana Falalyeyeva; Petro Bodnar; Tetyana Beregova
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

8.  A Mitochondrial VDAC1-Based Peptide Greatly Suppresses Steatosis and NASH-Associated Pathologies in a Mouse Model.

Authors:  Srinivas Pittala; Yakov Krelin; Yael Kuperman; Varda Shoshan-Barmatz
Journal:  Mol Ther       Date:  2019-07-12       Impact factor: 11.454

9.  Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without.

Authors:  Chia-Ming Chu; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2012-08-18       Impact factor: 3.199

10.  Hepatic differentiated embryo-chondrocyte-expressed gene 1 (Dec1) inhibits sterol regulatory element-binding protein-1c (Srebp-1c) expression and alleviates fatty liver phenotype.

Authors:  Lian Shen; Anfang Cui; Yuan Xue; Ying Cui; Xueyu Dong; Yong Gao; Hao Yang; Fude Fang; Yongsheng Chang
Journal:  J Biol Chem       Date:  2014-07-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.